AUS
NZ
UK
CA
USA
IND
Highlights
- Memphasys pilot validates RoXsta’s rapid diagnostic capabilities
- RoXsta processes 96 samples in under an hour
- Potential applications span human fertility and veterinary science
Memphasys (ASX:MEM) has reported a successful pilot study of its RoXsta Mega Cell diagnostic platform, showcasing the system’s ability to conduct high-volume antioxidant testing quickly and accurately—an achievement that positions the company at the forefront of bioanalytical innovation within the healthcare sector.
RoXsta is engineered to deliver fast and precise measurements of reactive oxygen species (ROS), key markers for oxidative stress in biological samples. In the recent lab trial, the device analyzed 96 samples in under one hour with high accuracy. This rapid throughput marks a significant improvement over traditional antioxidant diagnostic methods, potentially opening new avenues for clinical and research-based applications.
One area showing immediate promise is male fertility. According to Memphasys, RoXsta's results have shown a strong correlation between oxidative stress and sperm health, making the platform especially relevant for infertility diagnostics. The technology also offers potential in veterinary medicine, particularly within the thoroughbred horse racing industry, where oxidative stress and physical performance are closely linked.
Oxidative stress, which results from an imbalance between free radicals and antioxidants in the body, has been associated with a range of health conditions—from reproductive challenges to degenerative diseases and diminished athletic performance. RoXsta’s ability to pinpoint ROS levels with speed and precision could significantly improve patient outcomes and streamline testing workflows in commercial laboratories.
Dr. David Ali, managing director at Memphasys, noted that the positive pilot results build strong momentum for RoXsta's next phase of development. With an eye on commercial scalability, the company aims to optimize the platform for broader deployment across healthcare and research sectors.
This innovation comes as the broader Australian market continues to foster medical and biotechnology growth. Companies focused on advanced diagnostics may offer diversification potential to investors tracking the ASX200, particularly those also exploring sectors like ASX dividend stocks, where growth and income strategies intersect.
Compared to other antioxidant diagnostic platforms, RoXsta stands out not only for its speed but also its cost-effectiveness, offering a compelling option for institutions seeking real-time insights at lower operational expenses. As Memphasys continues development, RoXsta may play an increasingly vital role in how oxidative stress is monitored and managed—both in human health and veterinary contexts.
